Red Meat Tied to High RA Risk; Fruits and Veggies Protective
The risk for developing rheumatoid arthritis (RA) rose with a high intake of red and processed meat vs fruits and vegetables in a case-control study.
METHODOLOGY:
The risk of developing RA based on dietary habits was explored in a Swedish nested case-control study within a prospective study conducted between January 1991 and September 1996 (n = 28,098).
Diet was assessed at baseline using a 7-day menu book, a 168-item questionnaire, and an interview lasting 45-60 minutes, and each RA patient was matched to four control individuals for analysis.
Compliance with the 2015 Swedish Dietary Guidelines for intake of fiber, fruits and vegetables, fish/shellfish, added sugars, and red or processed meat was scored and categorized as low, moderate, or high.
Data from registries and validated electronic medical records identified RA incidence through December 2016; data on rheumatoid factor and anticyclic citrullinated peptide antibody were also retrieved.
TAKEAWAY:
A total of 305 incident cases of RA were identified (76.1% women; 66.9% seropositive), with a mean age of 56.8 years at baseline and an average 12-year interval until diagnosis.
Consuming < 500 g/wk of red and processed meat (adjusted odds ratio [aOR], 0.60; 95% CI, 0.38-0.97) and ≥ 400 g/d of vegetables and fruits (aOR, 0.64; 95% CI, 0.43-0.94) significantly reduced the odds of developing RA.
Lower odds of developing RA were linked to fruits and vegetables (aOR per SD, 0.70; 95% CI, 0.57-0.87) and fiber (aOR per SD, 0.80; 95% CI, 0.64-0.99) vs higher odds with red and processed meat (aOR per SD, 1.31; 95% CI, 1.07-1.59).
Adhering to intake guidelines for all food types was linked to a lower risk for seropositive RA; higher odds were linked to higher consumption of red and processed meat (aOR, 3.43; 95% CI, 1.69-6.96).
IN PRACTICE:
'[The study] findings suggest a dose-response relationship between red/processed meat intake and the risk of seropositive, but not seronegative, RA. This study helps to improve our understanding of the effects of dietary components in RA development, particularly for red and processed meats, but the exact mechanisms behind our findings need further investigation,' the authors concluded.
SOURCE:
This study was led by Rebecka Bäcklund, Lund University, Malmö, Sweden. It was published online on July 10, 2025, in Annals of the Rheumatic Diseases.
LIMITATIONS:
The diet was assessed only at baseline. Data were retrieved from a study that examined the association between diet and cancer, which may have introduced selection bias. Dietary guidelines, especially regarding meat intake, may have changed over time.
DISCLOSURES:
This study received support from the Swedish Rheumatism Association, the Gustav V 80-year fund, the Greta and Johan Kock foundation, and others. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
'The air was so dangerous in my Birmingham postcode I ended up on life support'
A Birmingham resident who lived near the city's landmark motorway, the Spaghetti Junction, has revealed how she ended up on life support. Named only as Jenny, the 75-year-old woman said she 'never realised how dangerous the air was' until she was hospitalised with life-threatening pneumonia. Traffic fumes and poor housing conditions were to blame for her deteriorating health, doctors told her at the time. Living next to the busiest motorway in Europe, she also found herself suffering regular asthma attacks just from stepping outside. Read more: Couple who starved their dog told RSPCA inspectors she was 'given to them by drug dealers' The retiree found her health drastically improved when she moved nearer to green spaces and away from the motorway. Speaking as part of a new Health Equals campaign this week, she said: 'I never realised just how dangerous the air I was breathing every day really was, I used to live near Spaghetti Junction, and would suffer regular asthma attacks just from stepping outside my door. "It wasn't until I ended up in hospital with pneumonia and on life support that doctors told me the traffic fumes and my poor housing conditions were to blame. "Everyone deserves clean air – not just those lucky enough to live near green spaces or away from busy roads. My health improved dramatically after I moved and started walking in parks. But not everyone has that choice." Her experience with air pollution comes as Health Equals, a coalition of 85 organisations, revealed World Health Organisation (WHO) air quality guidelines were breached in 35,000 neighbourhoods across Britain. Its report also outlined all 506 schools in Birmingham were in neighbourhoods failing the guidelines, putting 290,000 children at risk of serious long term health problems, including heart disease and stroke. The new findings are being released as part of Health Equals' Make Health Equal campaign, to highlight alarming health inequalities: where toxic air, alongside other issues including poor income, unstable jobs and unsafe homes, are contributing to an alarming 16-year gap in life expectancy across the UK. Health Equals is calling for a cross-government strategy that prioritises action on these essential building blocks of health, to stop lives being cut short. City environment boss Coun Majid Mahmood said: "Poor air quality is a major risk to public health, and that is why we are committed to improving the city's air through our clean air strategy. 'Data published in October 2023 showed that our work to address the air pollutant, nitrogen dioxide, is delivering results, with pollution levels in Birmingham city centre slashed by almost 40 per centr since 2016, driven in part by the introduction of the Clean Air Zone. 'Across the city, a dedicated air quality monitoring programme of potential 'hotspots' in Birmingham has found that all sites are within the annual mean air quality objective. This three year monitoring project concluded in 2024 and sought to identify any locations where concentrations of nitrogen dioxide might exceed the annual mean air quality objective. I am pleased to confirm our evidence suggests that outside of the city centre area, air quality concentrations are within legal limits. 'We also monitor particulate matter, both coarse and fine fractions (PM10 and PM2.5), and all of our sites continue to show compliance with legal limits set by Government. We will continue to work with Government to further drive down concentrations of fine particles as we know these are the largest risk to health and we have extended our monitoring network to this end. 'This is supported by our mission to install year-round air monitoring equipment in schools a key component in this. These monitors come in tandem with accompanying education resources and lesson plans helping to inspire a new generation of Clean Air champions. Our work in this area is underpinned further by projects like 'Car Free School Streets', which seeks to reduce emissions during rush hour, driven by readings from council monitoring data showing that the school gates are among the most polluted parts of the city. 'The school sensor programme has the co-benefit of providing monitoring data for fine particulate matter, recognised as a key pollutant in a range of adverse health outcomes such as heart disease, lung diseases and cancers. 'Furthermore, surplus revenues from the Clean Air Zone are feeding directly into our transport plan, enabling us to work in partnership with the West Midlands Combined Authority to support schemes related to active travel, improve public transport infrastructure, and manage demand in the city centre. 'Projects funded by Clean Air Zone revenues include a trial of hydrogen buses, upgrades to the University railway station and new stations on the Camp Hill line, as well as a number of projects within the Cross-City Bus scheme, the expansion of the Car Free School Streets programme, and development of the next phase of the Birmingham Cycle Revolution. Community grants for projects delivering against our priorities have also been provided through the Environment and Transport Neighbourhoods Fund (ETNF). 'Our work towards our clean air objectives continues with the recent launch of a consultation into the renewal of the city's Smoke Control Order, offering greater powers of enforcement against those who breach guidelines. This is just the latest step in our journey, which will not stop until we have achieved our objective of clean air for all residents.' Have you been affected by this. We would like to hear from you. You can contact us by emailing us on
Yahoo
23 minutes ago
- Yahoo
EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure
FOR IMMEDIATE RELEASE EnduroSat and Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure Sofia, Bulgaria & Geneva, Switzerland – July 28, 2025 – WISeKey International Holding AG (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, via its subsidiary AG, a company that focuses on space technology for secure satellite communication, specifically for IoT applications, and EnduroSat, a leading provider of software-flexible satellites, as part of their strategy to diversify partners in the industry, are pleased to announce the signing of a Memorandum of Understanding (MoU) to establish a framework aimed at achieving a strategic partnership to extend the development and deployment of ultra-secure, quantum-resilient nanosatellite systems for Internet of Things (IoT) applications. The cooperation targets the integration of SEALSQ secure elements, such as the VaultIC292, VaultIC408, and QS7001, into satellite payloads and ground-level endpoints. These components enable strong hardware-based security and digital identity protection, ensuring encrypted communications and trusted authentication across the IoT satellite network. The project aims to implement post-quantum cryptographic (PQC) algorithms, aligned with NIST recommendations such as CRYSTALS-Kyber and CRYSTALS-Dilithium, to safeguard against future quantum computing threats. WISeSat will provide the PQC algorithmic stack and support, while EnduroSat will incorporate these into its satellite and communication platform. EnduroSat brings its expertise in modular satellite design, in-orbit validation, and scalable deployment systems. It will lead the physical integration of SEALSQ secure components into next-generation satellite buses and contribute to the overall mission architecture. WISeSat will support cryptographic integration and field engineering resources, ensuring that each system meets high-security and resilience benchmarks. The partnership further outlines the future integration of post-quantum cryptographic solutions and secure elements into both EnduroSat and WISeSat satellite infrastructures. EnduroSat will also support the design and deployment of WISeSat's future missions, ensuring compliance with defined security and performance requirements. This collaboration builds on WISeSat's successful deployment of its new-generation PQC-ready nanosatellite in December 2025 and EnduroSat's proven record of delivering more than 60+ satellites to orbit for institutional, scientific, and commercial customers. The resulting architecture will offer scalable, tamper-proof IoT connectivity services from Low Earth Orbit (LEO), critical for use-cases in logistics, critical infrastructure, defense, and environmental monitoring. 'This partnership with EnduroSat marks a significant step forward in our mission to deliver quantum-resilient, end-to-end secure satellite infrastructure,' said Carlos Moreira, Founder and CEO of WISeKey. 'By integrating SEALSQ's advanced secure elements into the expanding WISeSat constellation, we are building a tamper-proof communications backbone in space. Together with EnduroSat's modular satellite technology, we are enabling scalable and ultra-secure IoT connectivity services from Low Earth Orbit—critical for securing data and infrastructure in the quantum era.' 'We are excited to initiate this partnership,' said Raycho Raychev, founder & CEO of EnduroSat. 'We hope to accelerate the introduction and establishment of much stronger encryption capabilities into the satellite industry.' About AG is pioneering a transformative approach to IoT connectivity and climate change monitoring through its innovative satellite constellation. By providing cost-effective, secure, and global IoT connectivity, WISeSat is enabling a wide range of applications that support environmental monitoring, disaster management, and sustainable practices. The integration of satellite data with advanced climate models holds great promise for enhancing our understanding of climate change and developing effective strategies to combat its impacts. As the world continues to grapple with the challenges of climate change, initiatives like WISeSat's IoT satellite constellation are essential for creating a more resilient and sustainable future. About WISeKeyWISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit About EnduroSatEnduroSat is a space infrastructure builder that engineers, builds, and operates exceptional satellites. The company streamlines space missions in LEO and beyond, handling every step from mission design to launch and operations. EnduroSat serves more than 360 customers globally and employs more than 230 space professionals across 6 locations worldwide. For more information, visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@ ENDUROSAT EADCompany Contact: Raycho RaychevFounder & CEOinfo@
Yahoo
23 minutes ago
- Yahoo
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros' mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company's recent successful €132M Series B financing, aimed at supporting the rapid development of nizubaglustat and the expansion of Azafaros' pipeline to other indications LEIDEN, Netherlands, July 28, 2025--(BUSINESS WIRE)--Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. "The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy." About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
